Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections

Patent metadata

Field	Value
Publication number	US-10954299-B2
Application number	US-201716303391-A
Country	US
Kind code	B2
Filing date	May 24, 2017
Priority date	May 24, 2016
Publication date	Mar 23, 2021
Grant date	Mar 23, 2021

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections. The increasing burden of antimicrobial resistance coupled with the decreasing number of antibiotics in development has urged for strategies to elaborate new therapies. The inventors showed a therapeutic effect of IL-20 receptor 10 antagonists in pulmonary bacterial infection mouse model. Indeed, they demonstrated that treatment with IL-20 receptor antagonists reduces bacterial burden, cellular infiltration and inflammation in bronchoalveolar lavage fluid (BALF) and lung. In particular, the present invention relates to an antagonist of IL-20 cytokines, or/and an antagonist of IL-20RB receptor for use in a method for the treatment of pulmonary bacterial infections in a subject in 15 need thereof.

First claim

The invention claimed is:

1. A method of decreasing a bacterial load from a pulmonary bacterial infection in a subject in need thereof comprising administering to the subject an antagonist of IL-20 cytokines or/and an antagonist of IL-20RB receptor in an amount sufficient to decrease the bacterial load.

2. The method of claim 1 wherein the IL-20 cytokines antagonist or/and the IL-20RB receptor antagonist is an antibody.

3. The method according to claim 1 , wherein the IL-20 cytokines antagonist or/and the IL-20RB receptor antagonist is administered to the subject in combination with antibiotics.

4. The method according to claim 1 , wherein the IL-20 cytokines antagonist or/and the IL-20RB receptor antagonist is administered to the subject in combination with corticosteroids.

5. The method according to claim 1 , wherein the IL-20 cytokines antagonist or/and the IL-20RB receptor antagonist is administered to the subject in combination with a bronchodilator.

6. The method according claim 1 , wherein the IL-20 cytokines antagonist or/and the IL-20RB receptor antagonist is administered to the subject in combination with a vaccine.

7. The method according to claim 1 , wherein the pulmonary infection is caused by a bacteria selected from the group consisting of the Aquaspirillum family, Azospirillum family, Azotobacteraceae family, Bacteroidaceae family, Bartonella species, Bdellovibrio family, Campylobacter species, Chlamydia species, Clostridium, Enterobacteriaceae family, Gardinella family, Haemophilus influenzae, Halobacteriaceae family, Helicobacter family, Legionallaceae family, Listeria species, Methylococcaceae family, mycobacteria, Neisseriaceae family, Oceanospirillum family, Pasteurellaceae family, Pneumococcus species, Pseudomonas species, Rhizobiaceae family, Spirillum Family, Spirosomaceae family, Staphylococcus, Streptococcus, Vampirovibr Helicobacter Family, and Vampirovibrio family.

8. The method of claim 2 wherein the antibody is a chimeric antibody, a humanized antibody or full human monoclonal antibody.

Assignees

• Inst Nat Sante Rech Med
• Centre Nat Rech Scient
• Pasteur Institut
• Univ De Lille 1 Sciences Et Technologies
• Univ De Droit Et De La Sante De Lille 2
• Inst Paseur De Lille
• Univ Lille

Inventors

• Gosset Philippe
• Madouri Fahima
• Pichavant Muriel

Classifications

• A61P31/04 Primary

  Antibacterial agents · CPC title

• C07K16/2866

  against receptors for cytokines, lymphokines, interferons · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title